Endocrine arterial hypertension: Therapeutic approach in clinical practice

Minerva Endocrinologica

Volumn 33, Issue 4, 2008, Pages 297-312

  Mazza, A ^a   Armigliato, M ^a   Zamboni, S ^a   Rempelou, P ^a   Rubello, D ^a   Pessina, A C ^b   Casiglia, E ^b  

^a ROVIGO GENERAL HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adrenalectomy; Antihypertensive agents; Hypertension

Indexed keywords

ALDOSTERONE; AMILORIDE; AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOTROPIN; CREATININE; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; ETOMIDATE; FELODIPINE; GLUCOCORTICOID; HYDROCORTISONE; KETOCONAZOLE; METYRAPONE; MINERALOCORTICOID; MITOTANE; NIMODIPINE; OCTREOTIDE; POTASSIUM; PREDNISOLONE; PROGESTERONE RECEPTOR; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; TRILOSTANE; UNINDEXED DRUG; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACNE; ADRENAL CORTEX CARCINOMA; ADRENAL HYPERPLASIA; ADRENALECTOMY; ANDROGEN SYNTHESIS; ANOREXIA; ATAXIA; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BREAST CANCER; CELL DEATH; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CREATININE BLOOD LEVEL; CUSHING DISEASE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG RESISTANCE; ELECTROLYTE DISTURBANCE; ERECTILE DYSFUNCTION; GYNECOMASTIA; HALLUCINATION; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE FILLING; HIRSUTISM; HOSPITALIZATION; HYPERALDOSTERONISM; HYPERTENSION; HYPERVOLEMIA; HYPOKALEMIA; IN VITRO STUDY; LETHARGY; LIBIDO DISORDER; LIDDLE SYNDROME; LIVER FAILURE; MORBIDITY; MORTALITY; NAUSEA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PARESTHESIA; POTASSIUM BLOOD LEVEL; RASH; REVIEW; SCREENING; SODIUM RETENTION; VERTIGO; ADRENAL DISEASE; ADRENAL TUMOR; DRUG COMBINATION; DRUG EFFECT; HUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

ADRENAL GLAND DISEASES; ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 60849123466     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
2. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006;98:121-8.
3. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Science 2007;113:267-78.
4. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Met 1999;84:2664-72.
5. Vaughan Jr. ED. Diseases of the adrenal gland. Med Clin North Am 2004;88:443-66.
6. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Mancia G. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998;31:68-72. (Pubitemid 28124694)
7. Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K et al. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism, Hypertension 1997;723-7. (Pubitemid 27097976)
8. Mazza A, Zamboni S, Armigliato M, Zennaro R, Cuppini S, Rempelou P et al. Endocrine arterial hypertension: diagnostic approach in clinical practice. Minerva Endocrinol 2008;33:1-20.
9. Lim PO, Young WF, MacDonald TM. A review of the medical treatment of primary aldosteronism. J Hypertens 2001;19: 353-61.
10. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF et al. Efficacy and tolerance of spironolactone in essential hypertension, Am J Cardiol 1987;60:820-5.
11. Zillich AJ, Carter BL. Eplerenone: a novel selective aldosterone blocker, Ann Pharmacother 2002;36:1567-76.
12. De Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L et al. Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6. (Pubitemid 17018455)
13. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002;15:709-16.
14. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;10:117-23.
15. Young WF Jr. Primary aldosteronism - treatment options. Growth Horm IGF Res 2003;13:S102-8.
16. Wisgerhof M, Carpenter PC, Brown RD. Increased adrenal sensitivity to angiotensin II in idiopathic hyperaldosteronism, J Clin Endocrinol Metab 1978;47:938-43. (Pubitemid 9047376)
17. Mantero F, Fallo F, Opocher G, Armanini D, Boscaro M, Scaroni C. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin Sci 1981;61:S289-93.
18. Griffing GT, Melby JC. The therapeutic effect of a new angiotensin-converting enzyme inhibitor, enalapril maleate, in idiopathic hyperaldosteronism. J Clin Hypertens 1985;1:265-76.
19. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR et al. Number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008;51:742-8.
20. Ganguly A. Primary aldosteronism. New Eng J Med 1998;339:1828-34.
21. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 2000;85:3313-8.
22. Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 1992; 9:319-22.
23. Stewart PM, Corrie JE, Shackleton CH, Edwards CR. Syndrome of apparent mineralocorticoid excess. A effect in the cortisol-cortisone shuttle. J Clin Invest 1988;82:340-9.
24. Findling JW, Raff H, Hansson JH, Lifton RP. Liddle's syndrome: prospective genetic screening and suppressed aldosterone secretion in an extended kindred. J Clin Endocrinol Metab 1997;82:1071-4.
25. Tsujihata M, Nonomura N, Tsujimura A, Nishimura K, Yoshimura K, Okuyama A. Laparoscopic adrenalectomy for primary hyperaldosteronism: clinical experience with 60 cases. J Endourol 2006;20:262-5.
26. Rossi GP. Surgically correctable hypertension caused by primary aldosteronism. Best Pract Res Clin Endocrinol Met 2006;20:385-400.
27. Sawka AM, Young WF Jr, Thompson GB, Grant CS, Farley DR, Leibson C et al. Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann Intern Med 2001:13:258-61. (Pubitemid 32799339)
28. Celen O, O'Brien MJ, Melby JC, Beazley RM. Factors influencing outcome of surgery for primary aldosteronism, Arch Surg 1996;31:646-50. (Pubitemid 26175585)
29. Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet 2006;367:1605-17.
30. Magiakou MA, Smyrnaki P, Chrousos GP. Hypertension in Cushing's syndrome. Best Pract Res Clin Endocrinol Met 2006:20:467-82.
31. Orth DN. Cushing's syndrome. N Engl J Med 1995;322:791-803.
32. Nieman LK, Ilias I. Evaluation and treatment of Cushing's syndrome. Am J Med 2005;118:1340-6.
33. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991;35:169-78.
34. Sonino N. The endocrine effects of ketoconazole. J Endocrinol Invest 1986;9:341-7.
35. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-201. (Pubitemid 20137851)
36. Misbin RI, Canary J, Willard D. Aminoglutethimide in the treatment of Cushing's syndrome. J Clin Pharmacol 1976;16:645-51.
37. Dewis P, Anderson DC, Bullock DE, Earnshaw R, Kelly WF. Experience with trilostane in the treatment of Cushing's syndrome. Clin Endocrinol (Oxf) 1983;18:533-40. (Pubitemid 13089442)
38. Sieber-Ruckstuhl NS, Boretti FS, Wenger M, Maser-Gluth C, Reusch CE. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary- dependant hyperadrenocorticism treated with trilostane. Domest Anim Endocrinol 2006;31:63-75.
39. Allolio B, Stuttmann R, Fischer H, Leonhard W, Winkelmann W. Long-term etomidate and adrenocortical suppression. Lancet 1983;2:626. (Pubitemid 13051068)
40. Giraldi FP, Scaroni C, Arvat E, Martin M, Giordano R, Albiger N et al. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf) 2006;64:219-24.
41. Boscaro M, Benato M, Mantero F. Effect of bromocriptine in pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 1983;19:485-91. (Pubitemid 13001510)
42. T'Sjoen G, Defeyter I, Van De SJ, Rubens R, Vandeweghe M. Macroprolactinoma associated with Cushing's disease, successfully treated with cabergoline. J Endocrinol Invest 2002;25:172-5. (Pubitemid 34232619)
43. Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing's syndrome. N Engl J Med 2005;352:2457-8.
44. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH secreting pituitary adenomas. Nat Med 2002;8:1281-7.
45. Hull SSA, Sheridan B, Atkinson AB. Preoperative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clin Endocrinol (Oxf) 2005;62:259-61.
46. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P et al. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004;151:173-8.
47. Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 2005;90:1340-6.
48. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003;2:999-1017.
49. O'Carroll AM, Krempels K. Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. Endocrinology 1995;136:5224-7.
50. Day R, Dong W, Panetta R, Kraicer J, Greenwood MT, Patel YC. Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labelling in situ hybridization analysis. Endocrinology 1995;136:5232-5.
51. Mezey E, Hunyady B, Mitra S, Hayes E, Liu Q, Schaeffer J et al. Cell specific expression of the sst2A and sst5 somatostatin receptors in the rat anterior pituitary. Endocrinology 1998;139:414-9.
52. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997;99:789-98. (Pubitemid 27097683)
53. Boerlin V, van der HJ, Beglinger C, Poon KW, Hartmann S, Dutreix C et al. New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 2003;26:S14-6.
54. Rickard AJ, Funder JW, Morgan J, Fuller PJ, Young MJ. Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration? Endocrinology 2007;148:4829-35.
55. Sonino N, Boscaro M, Fallo F, Fava GA. Potential therapeutic effects of ritanserin in Cushing's disease. JAMA 1992;267:1073.
56. Colao A, Pivonello R, Tripodi FS, Orio F Jr, Ferone D, Cerbone G et al. Failure of long-term therapy with sodium valproate in Cushing's disease. J Endocrinol Invest 1997;20:387-92.
57. Nussey SS, Price P, Jenkins JS, Altaher AR, Gillham B, Jones MT. The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome. Clin Endocrinol (Oxf) 1988;28:373-80.
58. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M et al. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 2006;147:4438-44.
59. Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985;61:536-40. (Pubitemid 15243969)
60. Christopoulos S, Bourdeau I, Lacroix A. Aberrant expression of hormone receptors in adrenal Cushing's syndrome. Pituitary 2004;7:225-35.
61. Daniel F, Kelly MD. Trans-sphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's syndrome. Neurosurg Focus 2007;23:E45.
62. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long term remission rates after pituitary surgery for Cushing's disease: the need for long surveillance. Clin Endocrinol 2005;63:549-59.
63. Newell-Price. Trans-sphenoidal surgery for Cushing's disease: defining cure and following outcome. Clin Endocrinol 2002;56:19-21.
64. Pereira AM, van Aken M, van Dulken H. Long-term predictive value of post surgical cortisol concentration for cure and risk of recurrence in Cushing's disease. J Clin Endocrinol Metab 2003;88:5858-64.
65. Toniato A, Boschin I, Bernante P, Opocher G, Guolo AM, Pelizzo MR et al. Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10 year experience. Ann Surg 2007;245:790-4.
66. Oyesiku NM. Stereotactic radiosurgery of Cushing's disease: a review. Neurosurg Focus 2007;23:E 14.
67. Lo CY, Lam KY, Wat MS, Lam KS. Adrenal pheochromocytoma a frequently overlooked diagnosis. Am J Surg 2000;179:212-5.
68. Roizen MF, Schreider BD, Hassan SZ. Anesthesia for patients with pheochromocytoma. Anesthesiol Clin North Am 1987;5:269-75.
69. Tauzin-Fin P, Sesay, M, Gosse, P, Ballanger, P. Effects of perioperative alpha1 block on haemodynamic control during laparoscopic surgery for pheochromocytoma. Br J Anaesth 2004;92:512-7.
70. Chew SL. Recent developments in the therapy of phaeochromocytoma. Expert Opinion on Investigational Drugs 2004;13:1579-83.
71. Chung PC, Ng YT, Hsieh JR, Yang MW, Li AH. Labetalol pretreatment reduces blood pressure instability during surgical resection of pheochromocytoma. J Formos Med Assoc 2006;105:189-93.
72. Ulchaker JC, Goldfarb DA, Bravo EL, Novick AC. Successful outcomes in pheochromocytoma surgery in the modern era. J Urol 1999;161:764-7.
73. Lebuffe G, Dosseh ED, Tek G, Tytgat H, Moreno S, Tavernier B et al. The effect of calcium channel blockers on outcome following the surgical treatment of pheochromocytomas and paragangliomas. Anaesthesia 2005;60:439-44.
74. Combemale F, Carnaille B, Tavernier B, Hautier MB, Thevenot A, Scherpereel P et al. Exclusive use of calcium channel blockers and cardioselective beta-blockers in the pre- and per-operative management of pheochromocytomas. 70 cases. Ann Chir 1998;52:341-5.
75. Steinsapir J, Carr, AA, Prisant, LM, Bransome ED Jr. Metyrosine and pheochromocytoma. Arch Intern Med 1997;157:901-6.
76. Sizemore GW, Scrogin KE, Weisenberg ES, Weldon-Linne CM, Madoo OB. Hypertensive crisis, catecholamine cardiomyopathy, and death associated with pseudoephedrine use in a patient with pheochromocytoma. Endocr Pract 2008;14:93-6.
77. Akiba M, Kodama T, Ito Y, Obara T, Fujimoto Y. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. World J Surg 1990;14:317-24.
78. Jaroszewski DE, Tessier DJ, Schlinkert RT, Grant CS, Thompson GB, van Heerden JA et al. Laparoscopic adrenalectomy for pheochromocytoma. Mayo Clinic Proceedings 2003;78:1501-4.
79. Col V, de Canniere L, Collard E, Michel L, Donckier J. Laparoscopic adrenalectomy for phaeochromocytoma: endocrinological and surgical aspects of a new therapeutic approach. Clin Endocrinol 1999;50:121-5.
80. Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol 2004;5:718-26.
81. Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 2004;136:1129-37.
82. Takahashi K, Ashizawa N, Minami T, Suzuki S, Sakamoto I, Hayashi K et al. Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Internal Medicine 1999;38:349-54. (Pubitemid 29254585)
83. Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr. Metyrosine and pheochromocytoma. Arch Intern Med 1997;157:901-6.
84. Eisenhofer G, Bornstein, SR, Brouwers, FM, Cheung NK, Dahia PL, de Krijger RR et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423-36.
85. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 2001;12:469-75.
86. Safford SD, Coleman, RE, Gockerman, JP, Moore J, Feldman JM, Leight GS Jr et al. Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003;134:956-62.
87. Pacak K, Fojo T, Goldstein DS, Eisenhofer G, Walther MM, Linehan WM et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst 2001;93:648-9. (Pubitemid 32409634)
88. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R et al. Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988;109:267-73.
89. Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005;90:2110-6.